Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas by Rodrigues, R F et al.
Chromosomal imbalances associated with anaplastic
transformation of follicular thyroid carcinomas
RF Rodrigues
l, L Roque*,1, J Rosa-Santos
2, O Cid
2 and J Soares
3
1Cytogenetic Laboratory, CIPM, Portuguese Cancer Institute, R. Prof Lima Basto 1099-023, Lisbon, Portugal;
2Head and Neck Surgery Department,
Portuguese Cancer Institute. R. Prof Lima Basto 1099-023, Lisbon, Portugal;
3Pathology Department, Portuguese Cancer Institute. R. Prof Lima Basto
1099-023 Lisbon, Portugal
The genetic alterations that underlie the progression of follicular thyroid carcinoma towards anaplasia are still largely uncharacterised.
We compared the Comparative Genomic Hybridization (CGH) profiles of 20 follicular (FTCs), 12 poorly differentiated (PDTCs) and
seven anaplastic thyroid carcinomas (ATCs), in order to identify the chromosomal imbalances potentially associated with cancer
progression. We found: (i) when considering that a ‘direct’ transformation of FTC towards anaplasia occurs, the defined significantly
important alterations were the increase of gains at 3q (Po0.05) and 20q (Po0.01), and the increase of losses at 7q (Po0.05) and
Xp (Po0.01); (ii) regarding poorly differentiated carcinomas as an intermediate independent entity in the anaplastic transformation of
follicular cancers, evidenced as important alterations towards anaplasia, were the proportional decrease in copy sequences at 7p, 7q,
12q and 13q resulting from the significant decrease of DNA gains at 7p and 12q (Po0.05), and the significant increase of losses at 7q
and 13q (Po0.05). These results unveil the chromosomal regions where genes of interest in thyroid anaplastic transformation are to
be located, and demonstrate that different gene dosage copy sequence imbalances are associated to the ‘direct’ pathway of
transformation of follicular into anaplastic cancers and to the progressive FTC-PDTC-ATC pathway.
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Thyroid malignant neoplasms of follicular cell derivation are
classified according to the World Health Organization (WHO)
criteria into well-differentiated papillary (PTCs) and follicular
(FTCs) carcinomas and undifferentiated or anaplastic carcinomas
(ATCs) (Hedinger et al, 1988). Clinical and pathological data
suggest that, in thyroid, PTC and FTC arise through distinct
pathways from follicular cells, and that both may dedifferentiate
into ATC (Williams, 1979; Wynford-Thomas, 1997). Poorly
differentiated thyroid carcinomas (PDTCs) identified by the
WHO as a subtype of well-differentiated tumours (WDTCs) show
morphological and clinical criteria in between WDTC and ATC,
and are identified by some as an intermediate distinct entity
between well-differentiated and anaplastic neoplasms (Sobrinho-
Simo ˜es et al, 2002). Genetic studies largely support this model, and
it is currently known that activation of RET, NTRK (Pierotti et al,
1996) and BRAF (Kimura et al, 2003), and overexpression of the
MET oncogene (Sua ´rez, 1998) contribute to the development of
PTC, whereas RAS point mutations (Sua ´rez, 1998) and PPARG/
PAX8 rearrangements (Kroll et al, 2000) are associated to FTC
genesis. The genetic events associated to the progression towards
anaplasia are, however, less understood. However, it was identified
that the frequency of P53 (Wynford-Thomas, 1997) and b-catenin
(Garcia-Rostan et al, 1999) mutations raised from WDTC to PDTC
to ATC, being significantly higher in the latter. Experiments
performed both in in vitro as well as in in vivo models clearly
demonstrated that they could not determine de per si anaplastic
thyroid transformation, and other genes ought to be involved in
that mechanism (Wynford-Thomas, 1997).
CGH analysis represents a useful method to identify the areas of
the genome where genes linked to the development and/or
progression of neoplasms are to be located. CGH studies in the
less-differentiated thyroid forms of cancer are restricted to 15
PDTCs and 38 ATCs (Hemmer et al, 1999; Wilkens et al, 2000;
Wreesmann et al, 2002). In PDTC, they were identified as the most
frequent changes losses at 11p11–31, 6p21 and 13q21–31. In ATC,
different chromosomal regions were identified as relevant.
Hemmer et al (1999) identified gains of 7p22-pter, 8q22-qter and
9q34-qter as the most frequent imbalances. Wilkens et al (2000)
defined gains of 5p and alterations of 8 as playing an important
role in the development of ATC, whereas, Wreesmann et al (2002)
proposed that gains at 3p13–14 and 11q13, and loss of 5q11–31,
were markers for anaplastic transformation.
In order to further characterise the genomic imbalances
associated with the development of anaplastic thyroid carcinomas,
we performed a CGH analysis in 12 PDTCs and seven ATCs, and
compared the obtained data with the CGH imbalances of 20
previously analysed FTC (Roque et al, 2003).
MATERIAL AND METHODS
Tumor specimens
In all, 20 FTC, 12 PDTC and seven ATC were included in this
study. In which concerns FTC, the median age of the patients
was 60 years (range from 33 to 87). The clinical and histological Received 10 September 2003; accepted 24 October 2003
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scharacteristics of this group of patients were those referred in
Roque et al (2003). Poorly differentiated thyroid carcinoma cases
were classified according to the criteria described in the Armed
Forces Institute of Pathology (AFIP) (Rosai et al, 1992). In the
PDTC group, six patients were females and five males. In case 10,
two different areas (A and B) from the tumour were analysed
(Table 1). The median age of patients with PDTC was 57 years
(range from 35 to 79). In the ATC group, all patients were females
(Table 2), being their median age 69 years (range from 51 to 77).
CGH
CGH analysis was performed from frozen material stored in
liquid nitrogen at the Cytogenetic laboratory – CIPM of the
Lisbon Portuguese Cancer Institute. Microscopic examination of
all tumour samples was performed before CGH analysis, in order
to be certain that in all cases at least 70% of the cells had the
histological characteristics of the group to which that specimen
was ascertain. DNA was isolated using a standard phenol-based
method (Sambrook and Russel, 2001).
CGH was performed according to the method of Kallioniemi et al
(1994) and as previously described (Roque et al, 2003). Briefly,
tumour DNA was labelled with biotin 16dUTP (Enzo-Roche) and
normal reference DNA with digoxigenin-11-dUTP (Enzo-Roche),
in a standard nick translation reaction. Equal amounts (400ng) of
labelled tumour DNA and labelled reference DNA were co-
precipitated with 15mg of Cot-1-DNA (Invitrogen) in ethanol.
After a 3-day hybridisation period, fluorescent detection of the
biotin- and digoxigenin-labelled DNAs was accomplished by using
avidin–FITC (Jackson Immunoresearch) and antidigoxigenin
rhodamine (Enzo-Roche) antibodies, respectively. Samples were
counterstained in DAPI in antifade solution (Vector).
For image acquisition, an epifluorescent microscope (Zeiss
Axioplan II) equipped with a cooled CCD camera (Photomic
Science) and a triple-band beam splitter and emission filters
(Chroma Technology, USA) were used. For each tumour, three-
colour images (blue, red and green) were acquired from at least 10
metaphases. Image analysis was performed using the CGH analysis
software from a CytoVision System (version 2.51 Applied Imaging,
Sunderland Tyne & Wear, UK).
Chromosomal regions were interpreted as gained when the red–
green profile ratio exceeded 1.25; as highly amplified when the
ratio exceeded 1.5; and under-represented when the ratio was less
than 0.75. Heterochromatic regions in chromosomes 1, 9, 16 and Y,
and the p arms of the acrocentric chromosomes were discarded
from the analysis.
Statistical analysis
For statistical analysis, we used the published CGH data of our 20
FTC (Roque et al, 2003). The statistical significance of the
differences in CGH imbalances between the three different
subgroups of thyroid neoplasms, FTC, PDTC and ATC, were
determined using Fisher’s exact test using STATA
tm 4.0 software.
Statistical significance was defined as a two-tailed Pr0.05.
RESULTS
CGH
The chromosomal imbalances observed in FTC were those referred
in Roque et al (2003). An overview of the observed alterations in
FTC is shown in Figure 1A.
All PDTC presented CGH imbalances (Table 1). Overall, DNA
gains were more frequent than losses (Figure 1B). No DNA losses
were detected at 3q, 5p/5q, 7q, 9q, 10p, 15q and 20p. Considering
only imbalances occurring in at least five tumours (this number
was empirically defined as a recurrence threshold), the most
frequent changes were gains of 7q occurring, respectively, in 75%
(nine out of 12) of the neoplasms, gains of 7p and 14q in 67%
(eight out of 12), gains of 12q in 58% (seven out of 12), gains of 1p,
5p/5q, 9p/9q, 12p and loss of 11q in 50% (six out of 12), and gains
of 18p and 20q in 42% (five out of 12). Minimal recurring regions
of gains were evidenced at 1p21, 3q24–25, 5p14, 7p12 and 7p15–
p13, 7q22, 9p13, 12q11–q13, 12q21, 14q13–q21 and 20p12.
Minimal regions of losses were defined at 11q23 and 13q21.
High-level amplifications were observed in case 4 of this group,
involving regions 5p15.1–q11 and 10pter–p11.2.
In the group of anaplastic carcinomas, all cases also presented
chromosomal imbalances (Table 2). An overview of the CGH
alterations observed in each of the cases is shown in Figure 2A.
Gains were detected in all chromosome arms; however, losses were
not observed in a series of regions: 1q, 3q, 4p, 5p, 6p/6q, 8q, 10q,
11p, 14q, 16p/16q, 19p/19q and 20p/20q. In ATC, the number of
chromosomal arms affected in imbalances in five or more cases
was lower than in the PDTC group. This might be due to the
smaller number of tumours evaluated (n¼7), but it might also
reflect a greater interneoplastic genetic heterogeneity. Only four
types of chromosomal imbalances were detected as recurrent
changes in at least five ATC: gains at 20p/q and losses of Xp in six
cases (86%), and gains at 3q and 5p in five of the tumours (71%).
At chromosome 7, a minimal region of loss was defined at 7q31.
The number of ATC presenting high-level amplifications was
higher than in the previous group. High-level amplifications were
detected in four of the seven ATC (57%), and different regions
were affected in each of the cases. The affected chromosomal
Figure 1 (A) Overview of the DNA copy number changes detected by
comparative genomic hybridisation in 20 follicular thyroid carcinomas, as
previously reported in Roque et al (2003). (B) Overview of the DNA copy
changes observed in the 12 PDTCs. Each line to the left side of the
chromosome ideograms represents a loss observed in one tumour, and
each line to the right side of the chromosome ideograms represents a gain
in one tumour. High-level amplifications are represented by thicker lines.
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qter, 18q 11.1-qter and chromosome 20.
Statistical analysis
Statistical analysis focused on the genomic differences between the
three groups of thyroid neoplasms, considering that in follicular
cancerigenesis there is a continuum of dedifferentiation and that
those imbalances detected as significantly different would harbour
genes involved in neoplastic progression. In the PDTC group, in
case 10, the two distinct tumour areas (A and B) were considered
as independent samples, since the obtained CGH results, although
similar, were not identical. We performed two types of statistical
evaluation, one considering that FTC may evolve ‘directly’ to ATC
and the other that PDTC represents an intermediate distinct entity
in the evolution of FTC towards ATC. In the former analysis, it was
identified as statistically significant between the two groups: the
increase of gains at regions 3q (Po0.05) and 20q (Po0.01), and
the increase of losses at 7q (Po0.05) and Xp (Po0.01). Between
FTC and PDTC, an increase in the frequencies of gains at: 7p, 9q
and 14q and a decrease in the frequencies of losses at 3q and 8q
were observed to be significantly different (Po0.05). Between
PDTC and ATC, the decrease in the frequencies of gains at 7p and
12q, and the increase in the frequencies of losses at regions 7q and
13q, were also statistically significant (Po0.05).
DISCUSSION
Malignant solid tumours are characterised by chromosomal
changes that reveal a tumour-specific distribution at early stages
of tumorigenesis. The acquisition of such aberrations is a
continuous process, and provides a random background of genetic
variability in the tumour. It is suggested that certain genetic
alterations that emerge in a cancer cell confer that cell a selective
advantage over the others, and cancer progression results from the
Table 1 Poorly differentiated thyroid carcinomas (PDTC)–clinical and CGH data
Case Sex/age CGH results
1 F/35 +2q23, +4q21–q28, +5p14, +5p11, +5q14–q22, +12q15–q21, +13q21, +14q13–q21
2 F/67  2q13–qter, +4q26–q28, +7pter–q21, +20,  22q13–qter
3 M/67 +1p21–p10, +1q12–q31,  1q44–qter,  2p16,  2q22–q23,  2q24.3–q34,  3pter–p26,  3p24.1,  3p14.1–p12,  4p15,  4q21.2–
q31.2,  4q32–qter, +5pter–q11, +5q31–q34, +6pter–p11,  6q21, +7,  8p23, +8q10–qter,  9pter–p22, +9q22–q32, +9q34,
+10q11–qter,  11p15.1 p13, +11q12–qter, +12,  13q21, +13q31–qter, +14q10–qter, +16p13–p11, +17, +18p11.3, +18p11.2–
q11.2, +20,  X,  Y
4 F/44 +1q21–q31, +2q11–q37, +3q24–q25, +4q22–q26, +5p15.1–q11
*, +6q25, +7p21, +7p15–p13, +7q21–q32, +9pter–p11,
+10pter–p11.2
*,  10q11.2,  11q21–q22,  11q23.2–qter, +14q24–qter,  16p11.2–p11.1,  Xp14–p11,  Xq28
5 F/75  1pter–p33, +1p31.1, +1p21, +3p12,  4pter–p13,  4cent, +5p14–p12, +5q11–qter, +6p11–q14, +7, +9pter–q11, +9q12–q22.1,
 10q26–qter,  11pter–p15,  11p11–q13,  11q23–qter,  12pter–p13,  12q24–qter, +13q21,+14,  17p13–p12,  17q11–q21,
 17q24–qter, +18p11.3,  18p11.1–q21, +18q22–qter,  19,  20p11.2–qter,  21q22.2–qter,  22, +X
6 M/67 +19,  22,  Y
7 M/58 +1pter–p13,  1q12, +1q23–q43, +2p25, +2p22–q35, +3pter–p21, +3q10–qter, +4pter–p14,  4q10–qter, +5,  6, +7pter–p15,
+7p14–p11.1, +7q11.2–q32, +8p21–qter, +9pter–p13, +9q10–q13, +10p11.2, +10q11.2–q23,  11, +12pter–q23, +12q24,  13,
+14q10–q24, +15q15–q23, +16p11.2,  17, +18p11.3, +18p11–q21, +20pter–p11.2, +20q13.3, +21q10–qter
8 F/79 +1p13,  3p21–p12, +3q22–qter, +5q11.2,  6, +7q11.2,  8pter–p11.2, +9p13, +10, +11q11–q14,  11q22–qter, +12p13, +12p11.2,
 13, +14q10–qter, +17p3, +17q21–qter, +18pter–q12,  18q21–qter, +19, +20p11.2, +20q13.1–qter,  X
9 M/50 +1p36.3–p31.3, +1p22–p13.3, +1q12–q32, +1q42–q43, +2p25–p21, +2p14–q11, +2q14.3–q35, +4p14–q11, +4q21, +4q27–
q31.2, +6p21.3, +6p21.1–q11, +6q21–q22,  7pter–p21, +7p12–q11.2, +7q22, +8p12–p11, +9p12–q21, +9q22.3,  10q10–qter,
+11p11.2,  11q13.5,  11q14–q23, +12q10–q13, +12q21, +13q11–q13,  14q21–qter, +15q22–q24, +16pter–q12.1,  16q12.2–
qter, +17p11.2–q24, +18p11.2–p10, +19p13.2–q13.1, +20p10–q12,  22q10–qter,  Y
10 A (Area A) F/38 +7, +12, +14, +X
10 B (Area B) F/38  6p21.3, +7, +9q31,  11q12–q13, +12, +14,  19,  21q22–qter,  22q12–qter, +X
11 M/42 +3p23–p21.3, +3p21.1–q26.3, +5p15.2–q14, +5q33, +9p12–q21, +12p11–q23, +16p11.2
F¼female; M¼male; * in bold–regions where high amplifications were observed.
Table 2 Anaplastic thyroid carcinomas (ATC)–clinical and CGH data
Case Sex/age CGH results
1 F/51  13
2 F/77  1pter–p13, +2,  3pter–p14, +3p12.1–qter*,  4q10–qter, +5p13–qter, +6pter–p10, +7pter–q22,  8pter–p23, +8q10–qter,
+9pter–p13*, +9p11–q12, +9q33–qter,  10pter–p11.2, +11q12–q13,  11q14.3–q23.2, +12pter–q12*, +16q10–q11.2,
+16q21–qter,  17p13.1–p11.2,  18, +19p13.2, +20,  Xpter–p10
3 F/74 +1pter–p13, +3pter–p23, +3p11.2–qter, +4q10–qter, +5,  7q22–q32, +11pter–p12, +13q34–qter, +14q12–qter, +18p11.1–
qter*, +19q12–q13.1, +19q13.3, +20,  Xpter–Xq22
4 F/72 +1pter–p36, +1p35, +1p32, +1p31.1–p22,  2q33–qter, +3q26–qter,  4q33–qter, +5pter–p10*, +7pter–p21,  7q31, +9pter–
p24,  9p21–p12,  12pter–p11.1,  13q10–q21, +14q10–qter*, +15q21–qter, +19p12.1, +19q13.2, +20,  Xpter–p11.1,  Xq10–
qter
5 F/66 +1pter–p13, +1q12–q21, +1q25–qter, +2p23–p15, +2q14.1–q24,  3pter–p25, +3q11.2–qter, +4pter–4q31.3, +5pter–q33,
+6p23–q15*, +6q22, +7pter–p21,  7q10–qter, +8q10–qter,  9pter–p24, +10pter–p11.2, +11q12,  11q14–qter,  12p12,
+12q14–q21.3, +14q10–qter, +15q10–qter, +16q10–qter,  17p12–p11, +17q22–qter,  18p11–qter, +19p13.1–p11.2, +20p11–
qter, +21q21.2–qter,  X
6 F/77  2pter–p24, +2q23–q32, +2q33.2–q35,  3p14–p12, +4p15.2–q32, +5p11–qter, +7q22–q34,  8pter–p12, +8q10–qter,  9pter–
p21, +9q22–qter, +10, +12pter–p11,  12q15–qter,  13q12–q31,  15q10–qter,  17pter–p11,  17q11–q22, +20p11.2–qter,
+21q21.1–qter, +22q11–qter,  Xpter–p11.2
7 F/64 +1pter–p13,  2q33, +3q27,  4q33–qter,  5q13–q21, +9pter–p22, +9q22–qter, +10q24–qter, +12pter–p13,  13q21–q33,
+14q32–qter, +17, +19pter–p10, +20p11–qter,  21q11.2–q21, +22q12–qter,  Xp11.2–q13.
F¼female; M¼male;* in bold–regions where high amplifications were observed.
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sexpansion of clone(s) that collectively acquires the following
characteristics: self-sufficiency in growth signals, insensitivity to
anti-growth signals, evasion to apoptosis, sustained angiosenesis,
limitless replicate potential and capacity of tumour invasion and
metastasis (Hanahan D and Weinberg RA, 2000).
In thyroid, the chromosomal imbalances associated with
anaplastic transformation of follicular thyroid carcinomas are still
largely uncharacterised. On the basis that in a significant number
of patients anaplastic cancers develop suddenly after a long period
of a neoplasm of the differentiated type has been diagnosed, we
compared the frequency of chromosomal imbalances in FTC and
ATC, as an approach to decipher the genetic factors implicated in
this process. Accordingly, we identified that gains of 3q and 20q
and losses of 7q and Xp are to play a significant role in committing
follicular cancer cells to anaplasia (Figure 2B).
Gains at 3q were observed in five of the seven ATC tumours and
a high-level amplification (HLA) was detected in case 2. Several
candidate genes are mapped at 3q, which may be deregulated by
copy number increase and may be involved in cellular dediffer-
entiation, for example, SST, PI3K, or BCL-6. PI3K is a member
of a cell signal pathway that is activated by tyrosine kinases via
its regulatory p85 subunit, or by RAS via its catalytic p110 subunit
(De Vita et al, 2000). In thyroid cells, it was reported (Cass et al,
1999) that activation of PI3K confers a TSH independent DNA
synthesis, and it was demonstrated (Gire et al., 2000) that in
primary human thyroid cells PIK3 is an absolute requirement for
the proliferative response to RAS. RAS-activating point mutations
are reported to occur at a high frequency (from 55 to 100%) in
undifferentiated thyroid cancers (Sua ´rez, 1998), and thus it is
conceivable that an increase in PI3K copy number is implicated in
proliferative advantage in these tumours.
A number of genes related to invasion and metastasis (e.g.
MMP9 and MMP24), cell cycle and mitotic checkpoints (e.g.
STK15) are assigned to 20q. Our findings of a significant
association (Po0.01) between 20q over-representation and ana-
plasia are in keeping with previous results, which reported that 20q
gains were only detected in PDTC and ATC (Wreesmann et al,
2002), and with studies performed in thyroid in vitro models
(Zitzelsberger et al, 2001). Zitzelsberger et al (2001) detected that
20q gain was an important alteration acquired by thyroid cells in
order that they could be able to cause tumours in athymic mice.
Interestingly, the authors of this study verified that tumorigenecity
in mice required the co-presence of deletions of 9q32–q34 and
7q21–q31, and that varying combinations of these three aberra-
tions could contribute to a more aggressive behaviour.
In our series, we also identified a statistically significant
association (Po0.05) between 7q losses and ATC. The common
deleted region to all cases with 7q loss in this group of tumours
was 7q31. The second most common aphidicolin-inducible fragile
site of the human genome (Fra7G) has been located in this region,
and loss of heterozygosity (LOH) studies indicate this chromoso-
mal region as a frequent site of allele loss in a variety of tumours
(Zenklusen et al, 2000). In the thyroid gland, it was proposed
(Trovato et al, 1999) that 7q31 was the site of at least one
suppressor gene involved in follicular tumorigenesis.
Six of the seven anaplastic tumours of this series presented
deletions at the short arm of the X-chromosome, and a highly
significant association (Po0.001) was detected between Xp sequence
losses and ATC. An association between Xp loss and undifferentiated
thyroid cancers has not been previously reported by CGH or by any
other technique (Ward et al,1 9 9 8 ;K i t a m u r aet al, 2001). The DNA
losses detected by CGH in our cases were extensive, and we were not
able to define minimal chromosomal region(s) of deletions, which
may be explained by the limitations of the CGH technique.
Alternatively, we may consider that under-representation of a series
of genes at Xp may interact or modify the expression of other genes,
and therefore promote the progression towards anaplasia. Wynford-
Thomas (1997) proposed, based on the use of viral oncogenes
(SV40) to mimic the effect of tumour-suppressor gene function loss,
that one of the cooperating events of P53 in thyroid anaplastic
cancer could be of epigenetic nature, rather than mutational. Our
findings of extensive Xp loss with a highly significant association
with ATC make this an attractive hypothesis to explore.
Poorly differentiated thyroid carcinomas consist in a morpho-
logical and biologically heterogeneous group of tumours that have
been proposed to represent an intermediate independent entity in
between WDTC and ATC, and not only a subtype of WDTC
(Sobrinho-Simo ˜es et al, 2002). In keeping with the above proposal,
we compared our data in order to determine the genetic imbalances
with a significant importance in this progression pathway.
Accordingly, we identify that a proportional increase in copy
sequences at 3q, 7p, 8q, 9q and 14q, resulting from the significant
increase of DNA gains at 7p, 9q and 14q, and the significant
decrease of DNA losses at 3q and 8q, would commit the follicular
cancer cell to a poorly differentiated phenotype (Figure 2B). CGH
data on PDTC are scarce and we are aware of only a report by
Wreesmann et al (2002) describing chromosomal imbalances in 15
PDTC. At variance with our results, they are found to be present in
PDTC but not in well-differentiated cancers: gains at 1p34–36,
6p21, 9q34, 17q25 and 20q, and losses at 11p11–31, 2q23–33,
4q11–13, 6q21 and 13q21–31. Interestingly, the series of WDTC
Figure 2 (A) Overview of the DNA copy number changes detected by
comparative genomic hybridisation in the seven anaplastic thyroid
carcinomas. Each line to the left side of the chromosome ideograms
represents a loss observed in one tumour, and each bar in the right side of
the chromosome ideograms represents a gain in one tumour. High-level
amplifications are represented by thicker lines. (B) Schematic representa-
tion of the CGH copy sequences increases (m) and copy sequences
decreases (k) defined to be of significance in the two pathways of
dedifferentiation of follicular cancers towards anaplasia. FTC¼follicular
thyroid carcinomas, PDTC¼poorly differentiated thyroid carcinomas,
ATC¼anaplastic thyroid carcinomas.
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papillary tumours, a group of differentiated thyroid cancers which
is characterised by molecular and chromosomal aberrations
distinct from those that were ascertained to FTC development.
From the data obtained in this study, evidenced as important in
the progression of PDTC towards anaplasia, were the proportional
decrease in copy sequences at 7p, 7q, 12q and 13q, resulting from
the significant decrease of DNA gains at 7p and 12q, and from the
significant increase of losses at 7q and 13q (Figure 2B). Chromo-
somal imbalances defined to be of relevance in this pathway of
transformation were not identical to those previously referred to be
of importance in the ‘direct’ evolution of FTC to ATC. These results
are conceivable, taking in account the model that cancer
progression is a dynamic process and that in cells with distinct
genetic backgrounds the aberrations that continuously emerge and
ensure a more aggressive phenotype may not be identical in the
different cells. Overall, in the pathway of evolution of PDTC to
ATC, loss of sequences seems to represent critical events, namely
those observed at chromosomes 7 and 13. Loss of heterozygosity at
13q is a common event in a variety of endocrine tumours,
suggesting the involvement of oncosuppressor genes mapped at
this chromosomal arm in the pathogenesis of a broad number of
endocrine neoplasms. In thyroid neoplasms, LOH studies have only
focus at the 13q14 region, and an LOH rate of D20% was reported
in both benign and malignant tumours (Zedenius et al, 1996;
Kitamura et al, 2001). In our CGH study, DNA losses were observed
in all groups of neoplasms. However, whereas in follicular
carcinomas, we have defined two minimal regions of losses: one
at 13q12–14 and other at 13q32–qter (Roque et al, 2003), in PDTC
we identified 13q21 as the minimal region of loss. In ATC, large
areas of deletions were observed, always including loss at 13q21.
Our results suggest that genes involved in dedifferentiation are
probably located at 13q21, being distinct from those involved in the
pathogenesis of FTC. Of note is that Wreesmann et al (2002) in
their CGH analysis reported that deletions at 13q21–q31 were
exclusively observed in PDTC and ATC.
In conclusion, this study revealed two distinct pathways of
genomic imbalances in anaplastic transformation of follicular
thyroid carcinomas: one assigned with a ‘direct’ dedifferentiation
of FTC into ATC and the other associated with the existence of an
intermediate morphologic entity, the PDTC. This inventory of
genetic aberrations increases our knowledge of FTC progression
and provides useful indications towards the identification of the
genes involved.
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